

Why not “do simple things in a simple way”: Use of the Pap test as the first step in screening genetic stability for human cultured stem cell therapy?

Ana C. Irioda^{1,2}, Larissa Zocche², Carolina M. Souza², Reginaldo J. Ferreira^{2,3}, Eduardo Aliprandini², Ricardo C. Cunha², Julio C. Francisco², Luiz C. Guarita-Souza⁴, Mariester Malvezzi⁵, Miriam P. Beltrame⁵, Lismary A. F. Mesquita⁶, Diogo Kuczera⁷, Rafael G. Vargas⁷ and Katherine A. T. Carvalho^{1,2}

¹Cell Therapy and Biotechnology in Regenerative Medicine Department, The Pelé Pequeno Príncipe Institute, Child and Adolescent Health Research, Pequeno Príncipe Faculty, Av. Silva Jardim 1632, Box 80.250-200, Curitiba, Paraná, Brazil. ²Bioprocess Engineering and Biotechnology Department, Federal University of Paraná, Av. Coronel. Francisco Heráclito dos Santos 210, Box 81.531-970, Curitiba, Paraná, Brazil. ³Federal University of Technology, Cristo Rei 19, Box 85.002-490, Toledo, Paraná, Brazil.

⁴Cardiovascular Surgery Department, Costantini Hospital, Rua Rosa Kaint Nadolny 190, Box 81.200-290, Curitiba, Paraná, Brazil. ⁵ Hospital de Clínicas, Haematology Department, Federal University of Paraná, Av. General Carneiro, 181 – Box 85.002-490, Curitiba, Paraná, Brazil. ⁶Pathology Department, Santa Casa de Misericórdia Hospital, Praça Rui Barbosa 694, Box 80.010-030, Curitiba, Paraná, Brazil.

⁷Department of Genetic, Federal University of Paraná, Av. Coronel. Francisco Heráclito dos Santos 210, Box 81.531-970, Curitiba, Paraná, Brazil.

⁸These authors contributed equally to this work.

⁹Correspondance should be addressed to K.A.T.C. (e-mail: katherinecarv@gmail.com)

The aim of this study was to analyze adipose tissue-derived mesenchymal stem cells (AT-MSCs) using the Pap test as a first screening step to evaluate genetic stability. Human adipose tissue from six healthy female donors was obtained from elective liposuction procedures. The cells were isolated, cultivated at P2/P3, characterized by flow cytometric analysis, and differentiation induced. The AT-MSCs were stained by Papanicolaou staining and analyzed according to the Bethesda classification, and viability-apoptosis relationships were evaluated. The results of the Pap test for Sample I indicated high-grade alterations consistent with genetic instability; for Samples II-V, atypical cells of undetermined significance; and for Sample VI, normal cells. These results demonstrate the potential of using the Pap test as an initial screening step to evaluate the genetic stability of cultured AT-MSCs and also suggest its use for other adherent cells such as embryonic stem cells or induced pluripotent stem cells.

The promise of stem cell-based therapy for advancement of research in regenerative medicine has stimulated a great number of clinical trials, particularly for previously untreatable diseases. This promise has been borne out in the twentieth century with good results obtained with bone-marrow transplantation for oncohematological diseases with the first successful allogeneic bone-marrow transplant by Georges Mathé (1958), and for illnesses other than cancer by Robert Alan Good (1968), and optimized since that time using modern approaches^{1,2}.

Meanwhile, stem cell preclinical studies in ischemic cardiomyopathy have demonstrated heart function improvement with cell-based therapy, and have shown benefits in other tissues such as the spinal cord; thus, it is vital to transfer these treatments to humans in a clinical therapeutic setting³⁻⁶.

However, for new therapies, it is necessary to ensure the safety of processes and products in an efficient manner. Toward this aim, therapeutic use of biological products mandates the establishment and use of basic requirements known as Good Tissue Practices to prevent disease transmission, mix-ups, and cross-contamination, assuring safe cell therapy⁷.

When stem cell therapy is used for oncohematological diseases with bone marrow-derived cell transplantation, the protocol is well established for using fresh bone marrow cells or mononuclear cells from cryopreserved umbilical cord blood for allogeneic transplantation or cryopreserved mononuclear cells from peripheral blood for autologous procedures. All these procedures are conducted without cell cultivation to avoid modified cells. These protocols are rigorously controlled by the International Society for Hematotherapy and Graft Engineering (ISHAGE, www.celltherapysociety.org).

As with oncohematological diseases, cell-based regenerative therapy is expected to be useful in nonhematological diseases with cells of adult origin, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs); both cell types are self-renewing populations and have pluripotent capacities to regenerate various tissues: cartilage, bone, muscle tendons, and the nervous system^{8,9}. The three characteristics that define MSCs are a) plastic-adherent growth, b) expansion as undifferentiated MSCs under specific culture conditions with a panel of specific surface antigens, and c) in vitro or in vivo differentiation potential¹⁰.

MSCs could also be used for transplantation in cell-based therapy, and for this purpose, must be able to expand ex vivo under cultivation. They should be able to grow in flasks based in their characteristic of adherence to plastic. However, the literature has demonstrated that transplantation is limited by the number of MSCs; thus, better results are dependent on producing a great number of cells independent of their source and consequently, large numbers of cells are usually required for clinical applications. Transplantation is also limited by mortality of the transplanted cells after transplantation by apoptosis or macrophage activity independent of the autologous or allogeneic procedures used. For the same reasons, iPSCs must also undergo expansion under ex-vivo conditions.

These considerations highlight the need for the in vitro expansion of stem cells prior to their commitment into tissue-specific applications. Before bioreactors can be used, several factors must be considered, including the need to increase the number of cells, the capacity to support high cell densities in relatively small volumes, the ability to scale up the design, and standardization of the bioprocess, including the safety of the products¹¹.

Difficulties have been reported during cultivation of MSCs for expansion. Spontaneous transformation of murine hematopoietic MSCs (mMSCs) has been described by many authors, although there are contradictory results^{12,13}. However, another group observed spontaneous malignant transformation in a preclinical study in which the cells had modified characteristics after the third passage. Direct injection of cultured bone marrow-derived MSCs into immunocompetent mice has resulted in tumor formation, and a karyotype analysis showed that increased chromosome numbers and multiple Robertsonian translocations occurred at passage 3 coincident with the loss of contact inhibition^{14,15}. On the other hand, spontaneous transformation over the long-term in human MSCs (hMSCs) from bone marrow cultures has not been reported in other studies^{16,17}. In humans, one group observed spontaneous malignant transformation of adipose tissue-derived (AT)-MSCs in vitro¹⁸.

Ultimately, Røslund et al. (2009) conclusively demonstrated spontaneous malignant transformations in long-term cultured bone marrow-derived human MSCs (5–106 weeks)¹⁹. The possibility of cell modifications compromises the reproducibility and safety of generation of MSCs under standardized conditions. The consequence of these results was increased requirements to maintain safe cell therapy beyond the basic requirements and regulations of government health organizations to ensure the identity, purity, potency, and clinical efficacy of MSCs.

The Center for Biologics Evaluation and Research (CBER; Rockville, MD, USA), one of seven centers of the United States Food and Drug Administration, has described its approach to the regulation of stem cells for clinical trials in the United States under the heading of “human cells, tissues, and cellular and tissue-based products (HCT/Ps).”

The protocol governs quality control of cells by the FDA, excluding genetically modified cells, and primarily addresses safety concerns with cell differentiation to undesired cell types and potential uncontrolled cell proliferation or tumorigenicity²⁰. Others concerns about the safety of this type of therapy are related to the stability of the product and/or the cell line, specifically, the number of passages/doublings over time, and maintaining desired differentiation properties without karyotypic alterations²¹.

Currently, there are no stem cell therapies licensed for use in the United States, but there are many investigational therapies currently undergoing clinical trials authorized by CBER. Many therapies under development by researchers are in the preclinical phase or phase I in the USA as well as in other countries. According to the FDA website, the total number of North American clinical studies is 2165 and only 63 MSC-based therapies were in progress involving cell cultivation; these cells were from various tissues, including hematological, adipose, cornea, conjunctive, skeletal muscle, and oral mucosa²².

All of those proceedings impose great costs in translating these therapies to humans and barriers to democratization of advanced therapy approaches. If cell-based therapies could be made more efficient, more people could access their benefits; ideally, the cost of each step would be reduced, without prejudicing the safety of the therapy.

In our laboratory, over the last eight years, we have made morphological observations of undifferentiated MSCs from human bone marrow and adipose tissue up to P5 (not for transplantation use), reviewing and recording a diary of cultured cells using an inverted microscope for the purposes of research academics. We have observed some issues that would be of concern regarding the health of cultured MSCs for potential use in transplantation cell-based therapy. In developing countries, particularly

in Brazil where our group is established, we have limited financial resources and at times, we need to answer certain questions without great cost. Why not “do simple things in a simple way”²³?

With that concept in mind, we chose the Papanicolaou test, known as the Pap smear or cervical smear, a cytological analysis of exfoliated cells from the cervix originally described by George Papanikolaou in 1928²⁴. This test is efficient in diagnosing early abnormal changes in the cervical epithelium that could indicate the presence of cervical cancer, and is universally used for screening for cervical cancer in woman²⁵. Changes due to technological developments in other areas of science have resulted in significant increases in efficiency since the Pap test was first developed.

The possibility of analyzing cultured MSCs at low cost using the Pap test appears very attractive to avoid additional steps, as a first step why it is a simple and short procedure requiring laboratory equipment available to everyone, in contrast to the more cumbersome trial procedures required by the FDA, if, similar abnormalities as for squamous cells of the cervix can be demonstrated. The aim of this study was to analyze AT-MSCs using the Pap test.

RESULTS

Table 1 shows the results of the flow cytometric analysis for Samples I-VI, as well the viability/apoptosis relationships. The obtained cells were demonstrated to be MSCs from adipose tissue why the cells were marked with antibodies that are in consensus of adipose origin as well the cells were integrity preservation demonstrates by great viability and small apoptosis fraction; all samples have demonstrated the normal profile of undifferentiated adipose derived stem cells (Fig. 1), the cells were adherents and all

samples were capable of differentiation in lipid cells demonstrated by oil Sudan red and bone by alizarin osseous matrix identification, respectively (Fig. 2). The Pap test for Sample I showed high-grade alterations consistent with genetic instability (Fig. 3,4), Samples II-V contained atypical cells of undetermined significance (Figs. 5,6) and Sample VI comprised normal cells (Fig. 7).

DISCUSSION

These results demonstrate the potential for using the Pap test as the initial step of a screening methodology to ensure the genetic stability of cultured MSCs. As described by various authors, the difficulty in assuring accuracy in the Pap test is more in the preparation of cervical smears than in the analysis, because it is possible to use rescreening methods for negative results²⁶⁻²⁸.

It is much easier to obtain a thin and clean smear starting from a cell culture than from the cervical samples normally used in a conventional Pap test. It is therefore possible that the efficiency and accuracy of a Pap test to detect changes in cells from culture would be greater than in cervical cancer screening programs. The Pap test is used to differentiate cells in many types of specimens: cerebrospinal, abdominal, or pleural fluids; synovial tissues; tumor samples; or other materials containing cells²⁶⁻²⁸.

The cytopathological findings for the AT-MSC samples in this study may be explained by suppression of RNA polymerase II serine-2 phosphorylation. This suggests a conserved mechanism of transcriptional quiescence in various stem cells and, in the absence of telomerase expression, why AT has a slow turnover and AT-MSCs participate in tissue homeostasis and respond to tissue injury, but stay in a quiescent form prior to injury longer than others^{30,31}.

The AT is “aged”—the differentiated adipocytes as well their quiescent AT-MSCs—and these cells are likely at increased risk of genetic instability. The adult MSCs were demonstrated to differentiate in varying concentrations in both solid and hematopoietic tissues in blood suspension; however, while the pluripotentiality of AT-MSCs may be similar to those of hematopoietic origin, their genetic stability may not be^{32,33}. The abnormality findings in a previous study of AT-MSCs suggest that inclusion of the Pap test for both allogeneic and autologous donors would be valuable, because abnormalities may develop in cultured cells independent of the type of donor³⁴.

These finding suggests that the Pap test could be used not only for adult sources, but also for all adherent cells from embryos, fetuses, and adult tissue such as iPSCs or MSCs. The results of our study demonstrate the usefulness of the Pap test as the initial quality control step for cultured stem cell therapy, independent of the origin, source, or type of transplantation. This approach seems reasonable if identification of modified cells in this first step could avoid additional costs. If modified cells were present at this first step, they would not be considered safe for use in transplantation. The atypical cells and cells of unknown significance are not safe; they may not be pathogenic, but they may transform to cancer stem cells. Caution is required and the risk is not considered acceptable. If there were no modified cells according to the Pap test results, the next step of the screening procedure involving the karyotype analysis would be followed.

The limitations of this study were the small sample size evaluated, nevertheless the intention was not statistical approach to do as well this study have not made in vivo transplantation of those cells to nonobese diabetic or severe combined immunodeficient mice to test the sequence of the genetic instability for the sample with high-grade alterations. These results of "undetermined significance" should be followed up in

further studies. How would this affect the usefulness of those cells to obligate to discharge or go to the next step of the screening? This study has not proposed to answer that question.

Tsuji *et al.* (2010) has suggested with respect to iPSC transplantation that to await the results of injecting cells into mice and subsequent tumor development to exclude cells for transplantation after two months will increase the delay in deciding whether to use the cells²⁹. We concur, and further suggest that our results support the proposition to introduce the Pap test into the algorithm for screening cell modification as an initial step (Fig. 08). To contribute for the usefulness of this test as a screening step is the possibilities to exclude in the start of screening the cells that have definite and indubitable high-grade alterations.

ACKNOWLEDGMENTS

Financial support was received from Coordination for the Improvement of Higher Level -or Education- Personnel (CAPES) for Post-Graduation Student Grants.

COMPETING FINANCIAL INTERESTS

The authors declare that they have no competing financial interests.

Figure Legends

Flow Cytometric Analysis Histogram






Figure 1 Four-color staining immunophenotyping analyses of Sample I. The following rat antibody conjugates, coupled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), CyChrome (PE-Cy5), or allophycocyanin (APC) were used: CD45-PE-Cy5 (clone HI30), CD34-FITC (clone 581), CD49d-PE-Cy5 (clone 9F10), CD105-FITC (clone 266), CD73-PE (clone AD2), CD90-FITC (clone 5E10), and conjugated 7AD-annexin (Becton Dickinson). The respective isotype matched control was PE MoAb.

IN VITRO AT-MSC DIFFERENTIATION

a

Lipid cells



Osseous cells





Figure 2 Differentiated adipose tissue mesenchymal stem cells (AT-MSCs). Clones were stained with alizarin for osteogenesis and Oil Red O for adipogenesis. Samples I (above) and their controls (below), respectively.

Sample I




Figure 3 Pap test results, Sample I, human AT-MSCs. Papanicolaou stain, P2, 100× optical microscopy. **(a)** Cells with atypical mitosis (arrows) and **(b)** cell with an increased number of nuclei (arrow). The analysis result according to the Bethesda classification was high-grade alterations consistent with genetic instability.

Sample I




Figure 4 Pap test results, Sample I, human AT-MSCs. Papanicolaou stain, P2, 100× optical microscopy. **(a)** Cell with an increased number of nuclei (arrow) and **(b)** cell with an atypical and multilobulated nucleus (arrow). The analysis result according to the Bethesda classification was high-grade alterations consistent with genetic instability.

Sample III




Figure 5 Pap test results, Sample III, human AT-MSCs. Papanicolaou stain, P2, 100× optical microscopy. (a) Cell with a nucleus of increased size (arrow) and (b) cells with morphological normal aspects (arrow). The analysis result according to the Bethesda classification was atypical cells of undetermined significance.

Sample IV




Figure 6 Pap test results, Sample IV, human AT-MSCs. Papanicolaou stain, P2, 100× optical microscopy. **(a)** Cell with a double nucleus (arrow) and **(b)** cells with normal morphological aspects. The analysis result according to the Bethesda classification was atypical cells of undetermined significance.

Sample VI




Figure 7 Pap test results, Sample VI, human AT-MSCs. Papanicolaou stain, P2, 100× optical microscopy. **(a)** Cells with normal morphological aspects. Typical mitosis in telophase (arrow) and **(b)** Cells with normal morphological aspects. Typical mitosis in anaphase (arrow). The analysis result according to the Bethesda classification was normal cells.




Figure 8 Algorithm for screening cell modifications beginning with the Pap test.

METHODS

Isolation of adipose tissue-derived MSCs

Human abdominal AT from six healthy female donors was obtained and designated Samples I–VI (ages 47, 38, 24, 45, 35, and 41 years with body-mass index 22.3, 29.4, 24.7, 29.4, 22.8, and 23.6, respectively). Samples were obtained during elective liposuction procedures for plastic and cosmetic purposes under local anesthesia after

informed consent, following the guidelines of the Brazilian Ethics Committee on Use of Human Subjects and as approved by the Pequeno Príncipe Hospital Complex Ethics Committee, number 0617-08.

The AT-MSCs were isolated in accordance with Zuk *et al.* (2001)³⁵. The lipoaspirates were washed extensively with sterile PBS to remove contaminating debris and red blood cells. The washed aspirates were treated with 0.075% collagenase (type I, Sigma) in PBS for 30 minutes at 37 °C with gentle agitation. The collagenase was inactivated with an equal volume of DMEM/10% FBS and the pellet was centrifuged for 10 minutes at low speed before being resuspended in DMEM/F12/10% FBS with 1% antibiotic and filtered through a 100- μ m mesh filter to remove debris. The filtrate was centrifuged and plated onto conventional tissue culture plates and the samples were then characterized by flow cytometric analysis.

Cell characterization and viability–apoptosis relationships

Flow cytometric analysis (FACScalibur; Becton Dickinson) was performed to validate the MSCs from adipose tissue. The harvested cells from the culture dishes underwent flow cytometric analysis to characterize the immunophenotypic profile of cellular subsets using the surface markers CD45, CD34, CD49d, CD73, CD90, and CD105.

Viability–apoptosis relationships were characterized using conjugated 7AD-annexin. The procedure used was “stain then lyse;” lysis was performed after staining with monoclonal antibodies (MAb). The cells were incubated with the specific MAb panel for 15 minutes at room temperature in the dark, lysed (FACS lysing solution, Becton Dickinson), washed with 0.1% PBS, resuspended, and analyzed on a FACScalibur using CellQuest software (Becton Dickinson).

For the 4-color staining immunophenotyping analyses, the following rat antibody conjugates, coupled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), CyChrome (PE-Cy5), or allophycocyanin (APC) were used: CD45-PE-Cy5 (clone HI30), CD34-FITC (clone 581), CD49d-PE-Cy5 (clone 9F10), CD105-FITC (clone 266), CD73-PE (clone AD2), and CD90-FITC (clone 5E10). All antibodies were used at the concentrations recommended by the manufacturer. The respective isotype-matched control was PE MoAb.

Induced differentiation

Differentiated AT-MSCs and their clones were processed as described in Zuk *et al.* (2002)³⁶. Briefly, the AT-MSCs were washed extensively with sterile PBS to remove contaminating debris and were cultured in induction medium (DMEM/F12 and 10% FBS supplemented with the growth factors for each cell type: for adipogenic, 0.01 μ M 1,25-dihydroxyvitamin D3, 50 μ M ascorbate-2-phosphate, 10 mM β -glycerophosphate, and 1% antibiotic; and for osteogenic, 0.5 mM isobutyl-methylxanthine, 1 μ M dexamethasone, 10 μ M insulin, 200 μ M indomethacin, and 1% antibiotic).

Cytology and immunocytochemistry

Differentiated AT-MSCs and their clones were stained for the assays with alizarin for osteogenesis and oil Sudan for adipogenesis.

Papanicolaou staining

The Pap test is based on specific changes in the cytoplasm and/or nucleus of the epithelial cells of the cervix, which can be identified through light microscopy. In this

method, the sample cells are placed in a thin and uniform layer on cleaned and degreased glass slides, known as “conventional smears”. These smears are submersed in a fixative solution (usually absolute ethyl alcohol) and then colored. A combination of two coloring agents is used: a nuclear dye, Harris hematoxylin; and a mixture of two cytoplasmatic dyes, orange G and polychrome mixture (EA51)³⁷.

This dye combination highlights cellular aspects that are fundamental in differentiating normal squamous cells of the cervix from low- and high-grade squamous intraepithelial lesions (LSILs and HSILs, respectively)³⁸. These aspects include nuclear pigmentation, position, volume, and morphology; membrane regularity and integrity; and the chromatin arrangement. Other important parameters are the cellular size and shape, and the ratio of the nucleus to the cytoplasm, which is increased in pre-cancerous cells^{26,39}.

In this study, the AT-MSCs were seeded in 25-cm² flasks at 5×10^4 /mL, then cultured for 7–14 days to P2 and P3 until 70% confluence was reached. The cells were then cultured for three days on double-chamber slides, after which the cultures were ended and the stain applied directly to the slides. Undifferentiated AT-MSCs were stained by Papanicolaou staining. Each slide was immersed in vats containing the staining solutions in sequence for the appropriate immersion times in accordance with the manufacturer’s instructions (Newprov, Pinhais, Brazil). The slides were then mounted and observed under a light microscope. The analysis result was determined in accordance with the Bethesda classification as (a) normal cells, (b) atypical cells of undetermined significance, or (c) high-grade alterations consistent with genetic instability^{38,39}.

1. Perry, A. R. & Linch, D. C. The history of bone-marrow transplantation. *Blood Rev.* **10**, 215–219 (1996).
2. Sodani, P. *et al.* New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. *Blood* **104**, 1201–1203 (2004).
3. Guarita-Souza, L. C. *et al.* Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. *Circulation* **114**, 120–124 (2006).
4. Guarita-Souza, L. C. *et al.* Functional outcome of bone marrow stem cells: mononuclear versus mesenchymal stem cells after cellular therapy in myocardial scar in Wistar rats. *Transplant. Proc.* **38**, 1953–1954 (2006).
5. Chachques, J. C. Cellular cardiac regenerative therapy in which patient? *Expert Rev. Cardiovasc. Ther.* **7**, 911–919 (2009).
6. Attar, A. *et al.* An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. *Cytotherapy* **0**, i1–i7 (2010).
7. Marwaha, N., Saluja, K. & Sharma, R. R. Stem cell therapy: the need for current Good Manufacturing Practices. *Bull. PGI* **41**, 49–51 (2007).
8. Florian, M. C. & Geiger, H. Concise review: polarity stem cells, disease, and aging. *Stem Cells* **28**, 1623–1629 (2010).
9. Das, A. K. & Pal, R. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications. *J. Tissue Eng. Regen. Med.* **4**, 413–421 (2010).
10. Javazon, E. H., Beggs, K. J. & Flake, A. W. Mesenchymal stem cells: paradoxes of passaging. *Exp. Hematol.* **32**, 414–425 (2004).

11. Placzek, M. R. *et al.* Stem cell bioprocessing: fundamentals and principles. *J. R. Soc. Interface* **6**, 209–232 (2009).
12. Zhou, Y. F. *et al.* Spontaneous transformation of cultured mouse bone marrow–derived stromal cells. *Cancer Res.* **66**, 10849–10854 (2006).
13. Li, H. *et al.* Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. *Cancer Res.* **67**, 10889–10898 (2007).
14. Rubio, D. *et al.* Spontaneous human adult stem cell transformation. *Cancer Res.* **66**, 10849–10854 (2006).
15. Bapat, S. A., Mali, A. M., Koppikar, C. B. & Kurrey, N. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. *Cancer Res.* **65**, 3025–3029 (2005).
16. Bernardo, M. E. *et al.* Human bone marrow–derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. *Cancer Res.* **67**, 9142–9149 (2007).
17. Izadpanah, R. *et al.* Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. *Cancer Res.* **68**, 4229–4238 (2008).
18. Meza-Zepeda, L. A. *et al.* High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. *J. Cell. Mol. Med.* **12**, 553–563 (2008).
19. Røslund, G. V. *et al.* Long-term cultures of bone marrow–derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. *Cancer Res.* **69**, 5331–5339 (2009).

20. Halme, D. G. & Kessler, D. A. FDA regulation of stem-cell-based therapies. *NEJM* **355**, 1730–1735 (2006).
21. Condic, M. L. & Rao, M. Regulatory issues for personalized pluripotent cells. *Stem Cells* **26**, 2753–2758 (2008).
22. National Institute of Mental Health; University of Virginia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010 [cited 2010 July 17]. Available from: <http://www.clinicaltrials.gov/ct2/search>.
23. Shakespeare, W. *The Complete Works of William Shakespeare* (MCMLXXV by Crown Publishers, Inc, United States of America, Library of Congress Catalog Card Number: 74-28554 2002 (ISBN: 0-517-163020). Henry IV, Part I, 425-453 (1975).
24. Shingleton, H. M., Patrick, R. L., Johnston, W. W. & Smith, R. A. The current status of the Papanicolaou smear. *CA Cancer J. Clin.* **45**, 305–320 (1995).
25. Wallin, K. L. *et al.* Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. *N. Engl. J. Med.* **341**, 1633–1638 (1999).
26. Nanda, K. *et al.* Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Ann. Intern. Med.* **132**, 810–819 (2000).
27. Tavares, S. B. *et al.* Comparison of the performance of rapid prescreening, 10% random review, and clinical risk criteria as methods of internal quality control in cervical cytopathology. *Cancer* **25**, 165–170 (2008).
28. Utgawa, M. L. *et al.* Performance of 3 methods for quality control for gynecologic cytology diagnoses. *Acta Cytol.* **52**, 439–444 (2010).

29. Tsuji, O. *et al.* Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. *PNAS* **107**, 12704–12709 (2010).
30. Freter, R., Osawa, M. & Nishikawa, S.-I. Adult stem cells exhibit global suppression of RNA polymerase II serine-2 phosphorylation. *Stem Cells* **28**, 1571–1589 (2010).
31. Izadpanah, R. *et al.* Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. *Cancer Res.* **68**, 4229–4238 (2008).
32. Bochkov, N. P. *et al.* Aneuploidy of stem cells isolated from human adipose tissue. *B. Exp. Biol. Med.* **146**, 344–347 (2008).
33. Buyanovskaya, O. A. *et al.* Spontaneous aneuploidy and clone formation in adipose tissue stem cells during different periods of culturing. *B. Exp. Biol. Med.* **148**, 109–112 (2009).
34. Choumerianou, D. M. *et al.* Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. *Cell Prolif.* **41**, 909–922 (2008).
35. Zuk, P. A. *et al.* Multi-lineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng.* **7**, 211–226 (2001).
36. Zuk, P. A. *et al.* Human adipose tissue is a source of multipotent stem cells. *Mol. Biol. Cell.* **13**, 4279–4295 (2002).
37. Muntean, M. Cytological identification of the (pre)cancerous cervical lesions within a clinically asymptomatic female population. *Curr. Health Sci. J.* **35**, 176–179 (2009).
38. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. *JAMA* **262**, 931–934 (1989).

39. Apgar, B. S., Zoschnick, L. & Wright Jr., T. C. The 2001 Bethesda System terminology. *Am. Fam. Physician* **68**, 1992–1998 (2003).

Table 1. Immunophenotypic expression by flow cytometric analysis (%)

AT-MSC	CD34-	CD45-	CD49d+	CD73+	CD90+	CD105+	ANNEXIN-	7-AAD-
I (a)	99.64	99.43	84.07	99.58	99.67	98.55	95.59	95.02
II (b)	99.64	99.83	96.38	99.84	99.95	99.41	93.52	91.57
III (c)	98.81	99.99	94.09	99.12	99.52	99.84	86.31	87.02
IV (d)	96.68	99.85	93.74	99.66	99.86	99.80	95.22	92.65
V (e)	99.19	99.88	88.77	99.88	99.87	99.91	96.20	94.22
VI (f)	97.04	99.91	81.24	99.45	99.86	99.20	90.40	95.17

AT-MSC: adipose-tissue mesenchymal stem cells; CD34: CD34-FITC (clone 581); CD45:

CD45-PE-Cy5 (Clone HI30); CD49d: CD49d-PE-Cy5 (clone 9F10); CD73: CD73-PE (clone

AD2); CD90: CD90-FITC (clone 5E10); CD105: CD105-FITC (clone 266); 7-

AAD: conjugated 7AD-annexin; -: negative expression; +: positive expression.